These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 22929917

  • 21. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.
    Ines C, Donia O, Rahma B, Ben Ammar A, Sameh A, Khalfallah T, Abdelmajid BH, Sabeh M, Saadia B.
    Tumour Biol; 2014 Jul; 35(7):7163-75. PubMed ID: 24763823
    [Abstract] [Full Text] [Related]

  • 22. Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditions.
    Zhang H, Song J, Ren H, Xu Z, Wang X, Shan L, Fang J.
    PLoS One; 2013 Jul; 8(1):e54510. PubMed ID: 23355875
    [Abstract] [Full Text] [Related]

  • 23. No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations.
    Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K, Takeda M, Kominami K, Iishii T, Tanaka N, Matsubara N.
    J Int Med Res; 2007 Jul; 35(4):450-7. PubMed ID: 17697521
    [Abstract] [Full Text] [Related]

  • 24. Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas.
    Wark PA, Van der Kuil W, Ploemacher J, Van Muijen GN, Mulder CJ, Weijenberg MP, Kok FJ, Kampman E.
    Int J Cancer; 2006 Jul 15; 119(2):398-405. PubMed ID: 16477638
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
    Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, Loupakis F, Falcone A, Bearzi I, Cascinu S.
    Ann Oncol; 2012 Jul 15; 23(7):1706-12. PubMed ID: 22112971
    [Abstract] [Full Text] [Related]

  • 29. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
    Moon BS, Jeong WJ, Park J, Kim TI, Min do S, Choi KY.
    J Natl Cancer Inst; 2014 Feb 15; 106(2):djt373. PubMed ID: 24491301
    [Abstract] [Full Text] [Related]

  • 30. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
    Scholtka B, Schneider M, Melcher R, Katzenberger T, Friedrich D, Berghof-Jäger K, Scheppach W, Steinberg P.
    Cancer Epidemiol; 2009 Aug 15; 33(2):123-9. PubMed ID: 19679059
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
    Rao B, Gao Y, Huang J, Gao X, Fu X, Huang M, Yao J, Wang J, Li W, Zhang J, Liu H, Wang L, Wang J.
    Int J Colorectal Dis; 2011 May 15; 26(5):593-601. PubMed ID: 21404058
    [Abstract] [Full Text] [Related]

  • 33. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study.
    Dinu D, Dobre M, Panaitescu E, Bîrlă R, Iosif C, Hoara P, Caragui A, Boeriu M, Constantinoiu S, Ardeleanu C.
    J Med Life; 2014 May 15; 7(4):581-7. PubMed ID: 25713627
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.
    Pérez-Ruiz E, Rueda A, Pereda T, Alcaide J, Bautista D, Rivas-Ruiz F, Villatoro R, Pérez D, Redondo M.
    Tumour Biol; 2012 Dec 15; 33(6):1829-35. PubMed ID: 22791568
    [Abstract] [Full Text] [Related]

  • 37. Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum.
    Kaji E, Kato J, Suzuki H, Akita M, Horii J, Saito S, Higashi R, Ishikawa S, Kuriyama M, Hiraoka S, Uraoka T, Yamamoto K.
    J Gastroenterol Hepatol; 2011 Mar 15; 26(3):599-607. PubMed ID: 21332555
    [Abstract] [Full Text] [Related]

  • 38. Role of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. -765G>C PTGS2 polymorphism and NMSC risk.
    Cocoş R, Schipor S, Nicolae I, Thomescu C, Raicu F.
    Arch Dermatol Res; 2012 Jul 15; 304(5):335-42. PubMed ID: 22159575
    [Abstract] [Full Text] [Related]

  • 39. Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.
    Jin M, Long ZW, Yang J, Lin X.
    Pathol Oncol Res; 2018 Jan 15; 24(1):45-57. PubMed ID: 28188432
    [Abstract] [Full Text] [Related]

  • 40. Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.
    Bösmüller H, Kranewitter W, Webersinke G, Rumpold H, Hackl M, Fend F.
    Pathol Res Pract; 2011 Jun 15; 207(6):399-402. PubMed ID: 21536390
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.